Kissei Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Kissei Pharmaceutical has a total shareholder equity of ¥220.8B and total debt of ¥1.3B, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are ¥260.3B and ¥39.6B respectively. Kissei Pharmaceutical's EBIT is ¥3.8B making its interest coverage ratio -2.9. It has cash and short-term investments of ¥50.0B.
Key information
0.6%
Debt to equity ratio
JP¥1.26b
Debt
| Interest coverage ratio | -2.9x |
| Cash | JP¥49.96b |
| Equity | JP¥220.77b |
| Total liabilities | JP¥39.57b |
| Total assets | JP¥260.34b |
Recent financial health updates
No updates
Recent updates
Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00
Sep 24
Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00
Sep 09Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00
Jul 25Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00
Jul 11Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit
May 21Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year
May 09Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00
Mar 27Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00
Mar 13Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00
Feb 27Financial Position Analysis
Short Term Liabilities: 4547's short term assets (¥107.0B) exceed its short term liabilities (¥19.4B).
Long Term Liabilities: 4547's short term assets (¥107.0B) exceed its long term liabilities (¥20.1B).
Debt to Equity History and Analysis
Debt Level: 4547 has more cash than its total debt.
Reducing Debt: 4547's debt to equity ratio has reduced from 2% to 0.6% over the past 5 years.
Debt Coverage: 4547's debt is well covered by operating cash flow (272.3%).
Interest Coverage: 4547 earns more interest than it pays, so coverage of interest payments is not a concern.